New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
07:36 EDTFOLDAmicus Theraputics announces positive results from Phase 2 Chaperone-ERT study
Amicus Therapeutics announced positive preliminary results from all 4 dose cohorts in a Phase 2 study to evaluate the safety and pharmacokinetic, or PK, effects of the pharmacological chaperone AT2220 co-administered with enzyme replacement therapy, or ERT, for Pompe disease, Myozyme and Lumizyme. Myozyme and Lumizyme are the first and only approved treatments for Pompe disease. Based on the Study 010 results, Amicus expects to initiate a repeat-dose clinical study in Q3.
News For FOLD From The Last 14 Days
Check below for free stories on FOLD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
11:08 EDTFOLDHigh option volume stocks
Subscribe for More Information
11:06 EDTFOLDSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen discusses Amicus Therapeutics' Migalastat for Fabry's disease on an Analyst/Industry conference call to be held on July 23 at 2 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use